Israel Englander’s Vigil Neuroscience VIGL Stock Holding History

Israel Englander’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-279,253	Closed	-$2.22M	–	6499
2025 Q2	$2.22M	Buy	279,253 +265,678	+1,957%	+$1.19M	﹤0.01%	3791
2025 Q1	$24.2K	Sell	13,575 -330,239	-96%	-$741K	﹤0.01%	5611
2024 Q4	$584K	Buy	343,814 +65,058	+23%	+$192K	﹤0.01%	4626
2024 Q3	$948K	Sell	278,756 -56,051	-17%	-$208K	﹤0.01%	4324
2024 Q2	$1.34M	Buy	334,807 +301,678	+911%	+$1.03M	﹤0.01%	3877
2024 Q1	$113K	Buy	+33,129	New	+$103K	﹤0.01%	5547
2023 Q2	–	Sell	-71,381	Closed	-$699K	–	6728
2023 Q1	$699K	Buy	+71,381	New	+$802K	﹤0.01%	4388
2022 Q2	–	Sell	-19,930	Closed	-$140K	–	7543
2022 Q1	$140K	Buy	+19,930	New	+$263K	﹤0.01%	5999

Other funds holding VIGL

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Israel Englander's VIGL Position: Q3 2025 in Review

Israel Englander sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 279,253 shares — an estimated $2.22M sold.

Israel Englander first reported a position in VIGL in Q1 2022 and held it in 8 quarters. The position peaked at $2.22M in Q2 2025. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

Israel Englander reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
Israel Englander sold 279,253 Vigil Neuroscience shares in Q3 2025, an estimated $2.22M.
Israel Englander first reported a position in Vigil Neuroscience in Q1 2022 and held it in 8 quarters.
Israel Englander's Vigil Neuroscience position peaked at $2.22M in Q2 2025.
2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.